Apparent changes in the epidemiology and severity of multiple sclerosis

N Koch-Henriksen, M Magyari - Nature Reviews Neurology, 2021 - nature.com
Multiple sclerosis (MS) is an immunological disease that causes acute inflammatory lesions
and chronic inflammation in the CNS, leading to tissue damage and disability. As awareness …

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines

M Filippi, P Preziosa, BL Banwell, F Barkhof… - Brain, 2019 - academic.oup.com
MRI has improved the diagnostic work-up of multiple sclerosis, but inappropriate image
interpretation and application of MRI diagnostic criteria contribute to misdiagnosis. Some …

Multiple sclerosis: clinical aspects

J Oh, A Vidal-Jordana, X Montalban - Current opinion in …, 2018 - journals.lww.com
A number of recent advances have been made in the clinical diagnosis and prognostication
of multiple sclerosis patients. Future research will enable the development of more accurate …

Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

MT Wallin, WJ Culpepper, E Nichols, ZA Bhutta… - The Lancet …, 2019 - thelancet.com
Background Multiple sclerosis is the most common inflammatory neurological disease in
young adults. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) …

Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis

C Bridel, WN Van Wieringen, H Zetterberg… - JAMA …, 2019 - jamanetwork.com
Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

X Montalban, R Gold, AJ Thompson… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Ocrelizumab versus placebo in primary progressive multiple sclerosis

X Montalban, SL Hauser, L Kappos… - New england journal …, 2017 - Mass Medical Soc
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study

A Bar-Or, JC Calkwood, C Chognot, J Evershed… - Neurology, 2020 - neurology.org
Objective The phase IIIb A Study to Evaluate the Effects of Ocrelizumab on Immune
Responses in Participants With Relapsing Forms of Multiple Sclerosis (VELOCE) study …

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

C Barro, P Benkert, G Disanto, C Tsagkas, M Amann… - Brain, 2018 - academic.oup.com
Neuro-axonal injury is a key factor in the development of permanent disability in multiple
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid …

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

M Filippi, MA Rocca, O Ciccarelli, N De Stefano… - The Lancet …, 2016 - thelancet.com
In patients presenting with a clinically isolated syndrome, MRI can support and substitute
clinical information in the diagnosis of multiple sclerosis by showing disease dissemination …